Plasminogen Activator Inhibitor 1
"Plasminogen Activator Inhibitor 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A member of the serpin family of proteins. It inhibits both the tissue-type and urokinase-type plasminogen activators.
| Descriptor ID |
D017395
|
| MeSH Number(s) |
D12.644.861.695.500 D12.776.124.125.640 D12.776.872.695.500 D23.119.832.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Plasminogen Activator Inhibitor 1".
Below are MeSH descriptors whose meaning is more specific than "Plasminogen Activator Inhibitor 1".
This graph shows the total number of publications written about "Plasminogen Activator Inhibitor 1" by people in this website by year, and whether "Plasminogen Activator Inhibitor 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1995 | 1 | 0 | 1 |
| 1996 | 0 | 1 | 1 |
| 1999 | 0 | 2 | 2 |
| 2000 | 2 | 1 | 3 |
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 1 | 2 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 1 | 2 |
| 2015 | 0 | 2 | 2 |
| 2017 | 0 | 2 | 2 |
| 2018 | 0 | 1 | 1 |
| 2021 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Plasminogen Activator Inhibitor 1" by people in Profiles.
-
Inhibition of PAI-1 Promotes Lipolysis and Enhances Weight Loss in Obese Mice. Obesity (Silver Spring). 2021 04; 29(4):713-720.
-
Role of PAI-1 in hepatic steatosis and dyslipidemia. Sci Rep. 2021 01 11; 11(1):430.
-
Proteomic biomarkers of cognitive impairment in obstructive sleep apnea syndrome. Sleep Breath. 2019 Mar; 23(1):251-257.
-
Association Between Inflammatory Markers and Progression to Kidney Dysfunction: Examining Different Assessment Windows in Patients With Type 1 Diabetes. Diabetes Care. 2018 01; 41(1):128-135.
-
Kallistatin reduces vascular senescence and aging by regulating microRNA-34a-SIRT1 pathway. Aging Cell. 2017 08; 16(4):837-846.
-
Deficiency of plasminogen activator inhibitor 2 in plasma of patients with hereditary angioedema with normal C1 inhibitor levels. J Allergy Clin Immunol. 2016 06; 137(6):1822-1829.e1.
-
Longitudinal Association Between Endothelial Dysfunction, Inflammation, and Clotting Biomarkers With Subclinical Atherosclerosis in Type 1 Diabetes: An Evaluation of the DCCT/EDIC Cohort. Diabetes Care. 2015 Jul; 38(7):1281-9.
-
Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis. Am J Physiol Lung Cell Mol Physiol. 2015 Feb 15; 308(4):L344-57.
-
The predictive role of markers of Inflammation and endothelial dysfunction on the course of diabetic retinopathy in type 1 diabetes. J Diabetes Complications. 2015 Jan-Feb; 29(1):108-14.
-
Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes Care. 2013 Aug; 36(8):2317-23.